Oncologia, arriva un nuovo biosimilare
L’Agenzia Italiana del Farmaco ha autorizzato l’immissione in commercio a carico del Servizio Sanitario Nazionale del biosimilare di bevacizumab.
sat/red
L’Agenzia Italiana del Farmaco ha autorizzato l’immissione in commercio a carico del Servizio Sanitario Nazionale del biosimilare di bevacizumab.
sat/red
https://www.insiciliatv.it/
Precedente notizia
Agricoltura, Giansanti “Stiamo definendo il futuro del settore”
Cookie | Durata | Descrizione |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
I commenti sono chiusi.